An Open-label, Multicenter Study to Assess the Long -Term Safety of Hydrocodone Bitartrate (HYD) Tablets 20 to 120 mg Once-daily in Subjects With Moderate to Severe Chronic Nonmalignant and Nonneuropathic Pain

Trial Profile

An Open-label, Multicenter Study to Assess the Long -Term Safety of Hydrocodone Bitartrate (HYD) Tablets 20 to 120 mg Once-daily in Subjects With Moderate to Severe Chronic Nonmalignant and Nonneuropathic Pain

Completed
Phase of Trial: Phase III

Latest Information Update: 14 May 2016

At a glance

  • Drugs Hydrocodone (Primary)
  • Indications Pain
  • Focus Adverse reactions; Registrational
  • Sponsors Purdue Pharma
  • Most Recent Events

    • 14 May 2016 Post- hoc results presented at the 35th Annual Scientific Meeting of the American Pain Society
    • 13 May 2015 According to a Purdue media release, data from this study were presented at the 34th Annual American Pain Society Scientific Meeting 2015.
    • 29 Apr 2014 Results will be presented at the American Pain Society 33rd Annual Scientific Meeting, according to a Purdue media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top